RES Group
RES Group Inc. is a pioneer in Quantitative Systems Pharmacology (QSP) modeling since 2001, dedicated to accelerating and de-risking drug development through mechanistic QSP modeling. They offer services including FIH dose projections, toxicity projections, and support for early-stage drug development, with extensive experience in developing models for over 100 disease indications and modalities. The company has a proven track record with over 300 successful collaborations and nearly 100% repeat customers.
Industries
Nr. of Employees
small (1-50)
RES Group
Needham, Massachusetts, United States, North America
Services
Project-based development of mechanistic systems pharmacology models to support discovery and development decisions across indications and modalities.
Translational modeling and dose projection services to prepare dose justification and toxicity projections for IND and early clinical planning.
Physiologically-based and mechanism-based PK/PD modeling to predict human pharmacokinetics, explore half-life extension strategies, and compare modalities.
Mechanistic modeling to evaluate and predict adverse event risks (e.g., GI toxicity, cytopenias) and inform clinical dose/schedule selection.
Integration of modeling with experiments to optimize synthetic routes, maximize yield/minimize impurities, and model dissolution and formulation behavior.
Project-based development of mechanistic systems pharmacology models to support discovery and development decisions across indications and modalities.
Translational modeling and dose projection services to prepare dose justification and toxicity projections for IND and early clinical planning.
Physiologically-based and mechanism-based PK/PD modeling to predict human pharmacokinetics, explore half-life extension strategies, and compare modalities.
Mechanistic modeling to evaluate and predict adverse event risks (e.g., GI toxicity, cytopenias) and inform clinical dose/schedule selection.
Integration of modeling with experiments to optimize synthetic routes, maximize yield/minimize impurities, and model dissolution and formulation behavior.
Expertise Areas
- Quantitative systems pharmacology
- Translational PK/PD and PBPK
- First-in-human dose prediction
- Safety and toxicology modeling
Key Technologies
- Quantitative systems pharmacology (QSP)
- Physiologically-based pharmacokinetic (PBPK) modeling
- Mechanistic PK/PD modeling
- Computational fluid dynamics (CFD)
News & Updates
FDA approval of IND application for Solid Bio’s SGT-212, a gene therapy to treat Friedreich’s Ataxia
FDA approval of IND application for Solid Bio’s SGT-212, a gene therapy to treat Friedreich’s Ataxia, on January 7, 2025.
FDA approval of IND application for Astria’s STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis, on December 10, 2024.
FDA approval of IND application for Be Biopharma’s BE-101, engineered B cell medicine for the treatment of Hemophilia B, on May 28, 2024.
FDA approval of IND application for Solid Bio’s SGT-212, a gene therapy to treat Friedreich’s Ataxia
FDA approval of IND application for Solid Bio’s SGT-212, a gene therapy to treat Friedreich’s Ataxia, on January 7, 2025.
FDA approval of IND application for Astria’s STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis, on December 10, 2024.
FDA approval of IND application for Be Biopharma’s BE-101, engineered B cell medicine for the treatment of Hemophilia B, on May 28, 2024.